The online platform Made-in-China has entered into a settlement with the Connecticut attorney general’s office, agreeing to halt the sale of GLP-1 weight-loss medications to customers in the United States. According to a press release from the office of Attorney General William Tong, the platform had been facilitating the sale of "research grade" drugs that lacked both prescriptions and medical oversight.
Enforcement Action Against Unapproved GLP-1 Sales
The settlement addresses the distribution of drugs marketed as generic versions of popular medications, including Ozempic, Wegovy, Zepbound, and Mounjaro. While these brand-name drugs are FDA-approved for specific weight-loss and chronic condition treatments, the U.S. Food and Drug Administration has issued warnings regarding unapproved versions. These products have not undergone federal review for safety, effectiveness, or quality.
The attorney general’s office stated that the products sold through the platform were often falsely marketed. Analysis cited by the office indicated that the substances "contained impurities, potential bacterial contamination, and inconsistent quantities of active ingredients," which carry the risk of medication overdoses.
"There are currently no generic GLP-1 weight loss injections on the market, and anyone advertising or offering this is not telling the truth and exposing patients to potentially unsafe bootleg drugs," Attorney General Tong said in a statement. ABC News reported on the settlement Wednesday.
Monitoring and Financial Penalties
Under the terms of the agreement, Made-in-China has pledged to cooperate with ongoing investigations and will prevent manufacturers from using its platform to promote or sell GLP-1 medications to U.S. consumers. The company is now required to establish a monitoring system designed to identify and remove any such listings within five days.
The settlement includes a $300,000 penalty, though $270,000 of that amount will be suspended provided the company complies with the agreement. If the platform fails to adhere to these terms, it will face further penalties. Attorney General Tong noted that further regulatory measures are currently underway, adding that his office remains committed to taking decisive steps to ensure consumer and patient safety.
Rising Demand for Weight-Loss Medication
The crackdown follows a significant surge in the use of GLP-1 medications. Data from a November 2025 poll conducted by the nonprofit KFF indicates that approximately 12% of U.S. adults report using a GLP-1 drug to manage weight or treat chronic conditions like diabetes and heart disease. This figure represents a notable increase from the 6% of adults who reported using these medications in May 2024.
Frequently Asked Questions
Why are these "research grade" drugs considered dangerous?
The FDA warns that unapproved versions of GLP-1 medications have not been vetted for safety or quality. According to the Connecticut attorney general, these specific products were found to contain bacterial contamination and inconsistent active ingredients, which can lead to life-threatening overdoses.
Are there currently any generic versions of Ozempic or Wegovy available?
No. The attorney general’s office confirmed that there are no FDA-approved generic GLP-1 weight-loss injections on the market. Any product advertised as a generic version of these medications is unauthorized and potentially unsafe.
What is the status of the investigation into the platform?
The attorney general’s office noted that Made-in-China cooperated with the investigation and has committed to implementing a five-day removal cycle for any GLP-1 listings. The office stated that broader enforcement actions regarding the sale of illegal weight-loss drugs remain active.
Related reading